🔍

GLENMARK - Glenmark Pharma.

📊 NSE: GLENMARK 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 22:23

📢 Recent Corporate Announcements

Glenmark Receives U.S. FDA Approval for Progesterone Vaginal Inserts; Market Size $59.2 Million

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 09 Apr 2026, 08:50 AM

Glenmark Pharmaceuticals has received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg, which is a bioequivalent version of Endometrin®. The product will be distributed in the U.S. market, targeting a segment with annual sales of approximately $59.2 million as of February 2026. This approval strengthens Glenmark's presence in the women's healthcare space in North America. The launch is part of the company's ongoing strategy to expand its generic portfolio and improve medicine accessibility in the United States.

Received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg.
Product is bioequivalent and therapeutically equivalent to the reference drug Endometrin®.
Target market for the product achieved annual sales of approximately $59.2 million for the 12 months ending February 2026.
The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
Reinforces Glenmark's focus on the women's healthcare segment in the North American market.

💡 This is a positive development that adds a steady revenue stream to Glenmark's U.S. generic portfolio. Investors should monitor the company's ability to capture market share from the $59.2 million addressable market.

Glenmark Faces ₹32.11 Cr GST Demand and Penalty; Plans to Appeal

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 01 Apr 2026, 07:08 PM

Glenmark Pharmaceuticals has received an adjudication order from the GST authorities for FY 2019-20 and 2020-21. The order demands a tax amount of ₹16.05 crore along with an equivalent penalty of ₹16.05 crore, totaling approximately ₹32.11 crore excluding interest. The dispute involves the classification of a brand sale transaction as a 'mixed supply' subject to a higher GST rate. The company has stated it will contest the demand through an appeal and does not foresee a material impact on its financials.

GST demand of ₹16.05 crore raised for alleged short payment in FY 2019-20 and 2020-21
Equivalent penalty of ₹16.05 crore imposed under sections 74 and 122 of the CGST Act
Total financial implication excluding interest stands at approximately ₹32.11 crore
Dispute relates to the tax treatment of a brand sale transaction classified as mixed supply
Company intends to file an appeal and maintains there is no material impact on operations

💡 Investors should note this as a routine tax litigation matter; the financial impact is relatively small compared to the company's scale. No immediate action is required as the company plans to challenge the order.

Glenmark to Directly Commercialize RYALTRIS in U.S. Market from April 2026

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 01 Apr 2026, 05:30 PM

Glenmark Pharmaceuticals has announced a strategic shift to manage the end-to-end commercialization and distribution of RYALTRIS in the U.S., effective April 1, 2026. This move transitions the company toward a direct commercial presence for its first innovative product in the U.S. market. RYALTRIS is currently approved in major regions including the EU, UK, and China, and saw expansion into 11 new markets in FY26. By leading brand strategy and market access directly, Glenmark aims to enhance its responsiveness to market needs and strengthen its innovative portfolio.

Direct U.S. commercialization of RYALTRIS nasal spray to begin on April 1, 2026.
RYALTRIS is now present in 55 countries globally, following 11 new launches in FY26.
The product is a fixed-dose combination of olopatadine hydrochloride and mometasone furoate for allergic rhinitis.
Strategic shift aims to build a sustainable, direct commercial U.S.-based presence for Glenmark's innovative products.

💡 Investors should monitor the impact on operating margins as Glenmark scales its own sales and distribution infrastructure in the U.S. The success of this direct-to-market strategy for RYALTRIS will be a key indicator of Glenmark's ability to scale innovative products globally.

Glenmark Launches GLIPIQ (Semaglutide) in India; Weekly Treatment Starts at ₹325

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 21 Mar 2026, 12:28 AM

Glenmark Pharmaceuticals has launched GLIPIQ (Semaglutide) in India for Type 2 Diabetes management, positioning it as a highly affordable GLP-1 therapy. The weekly treatment cost is set between ₹325 and ₹440, significantly lower than existing options in this class. The drug is available in both vial and pre-filled pen formats across three dosage strengths (2mg, 4mg, and 8mg). This launch follows CDSCO approval based on successful Phase III clinical trials conducted within India.

Launched GLIPIQ (Semaglutide) with disruptive weekly pricing starting at ₹325.
Available in multiple formats including cost-effective vials and convenient pre-filled pens.
Offered in three strengths: 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL to support flexible dosing.
Approved by CDSCO following a Phase III clinical study demonstrating safety and efficacy in Indian patients.
Introduced 'Sankalp' patient support program to improve therapy initiation and long-term adherence.

💡 Investors should view this as a major growth driver for Glenmark's India business, as it enters the high-demand GLP-1 market with a significant price advantage. Monitor the adoption rate and market share gains in the diabetes segment over the coming quarters.

Glenmark Launches GLIPIQ (Semaglutide) in India; Weekly Treatment Starts at ₹325

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 21 Mar 2026, 12:15 AM

Glenmark Pharmaceuticals has launched GLIPIQ® (Semaglutide) in India for Type 2 Diabetes management, positioning it as a highly affordable GLP-1 therapy. The treatment is priced disruptively, with weekly costs ranging from ₹325 to ₹440, significantly lowering the entry barrier for patients. The product is available in both vial and pre-filled pen formats across three strengths: 2mg, 4mg, and 8mg. This launch follows CDSCO approval based on Phase III clinical trials and leverages Glenmark's existing expertise in the GLP-1 category.

Launched GLIPIQ® (Semaglutide) for Type 2 Diabetes with weekly treatment starting at ₹325.
Available in vial and pre-filled pen formats in 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL strengths.
Weekly treatment costs range from ₹325 to ₹440, aiming to disrupt the expensive GLP-1 therapy market.
CDSCO approved following a multicentre Phase III clinical study demonstrating safety and efficacy in Indian patients.
Introduced 'Sankalp' patient support program to improve therapy initiation and long-term adherence.

💡 Investors should monitor the market share gains in the diabetes segment as Glenmark uses aggressive pricing to disrupt the GLP-1 market. This move strengthens their domestic formulation portfolio and could drive volume growth in the chronic care segment.

Glenmark Gets US FDA Approval for Fluticasone Nasal Spray; Targets $384.7M Market

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 19 Mar 2026, 08:37 AM

Glenmark Pharmaceuticals has received final U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC), a bioequivalent to Flonase® Allergy Relief. The product will be distributed in the U.S. by Glenmark Therapeutics Inc. with a planned launch in April 2026. This marks the company's first entry into the OTC nasal spray segment in the United States. The addressable market for this product is estimated at approximately $384.7 million based on annual sales data ending March 2026.

Received final U.S. FDA approval for Fluticasone Propionate Nasal Spray USP (OTC), 50 mcg per spray.
Target market for Flonase® Allergy Relief equivalents is valued at approximately $384.7 million annually.
Official commercial launch in the United States is scheduled for April 2026.
Represents Glenmark's first approved nasal spray in the U.S. Over-the-Counter (OTC) space.

💡 Investors should monitor the successful commercialization of this product in April 2026 as it strengthens Glenmark's North American OTC portfolio. The entry into a $384M market segment provides a healthy revenue growth opportunity for the company's U.S. business.

Glenmark Receives US FDA Approval for $384.7M Market OTC Nasal Spray

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 19 Mar 2026, 08:34 AM

Glenmark Pharmaceuticals has received final U.S. FDA approval for its Fluticasone Propionate Nasal Spray (OTC), a bioequivalent to Flonase Allergy Relief. The product targets a significant market with annual sales of approximately $384.7 million as of March 2026. This marks the company's first entry into the U.S. OTC nasal spray segment, with a commercial launch scheduled for April 2026. The product will be distributed by its subsidiary, Glenmark Therapeutics Inc., USA.

Final U.S. FDA approval received for Fluticasone Propionate Nasal Spray USP, 50 mcg (OTC)
Targets a market with annual sales of approximately $384.7 million according to Nielsen data
Product is bioequivalent to the reference listed drug Flonase Allergy Relief Nasal Spray
Commercial launch in the United States is planned for April 2026
Represents Glenmark's first approved nasal spray in the U.S. OTC space

💡 Investors should monitor the launch in April 2026 as it strengthens Glenmark's U.S. portfolio and provides a new revenue stream in the high-value OTC segment. The stock may see positive sentiment due to the successful regulatory milestone in a competitive $384 million market.

Glenmark to Launch Potassium Phosphates Injection in US; Market Size ~$50.7 Million

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 16 Mar 2026, 08:43 AM

Glenmark Pharmaceuticals Inc., USA, is set to launch Potassium Phosphates Injection USP in multiple dosage forms starting March 2026. The product is a therapeutic equivalent to Fresenius Kabi’s reference drug and targets the institutional channel in the US. According to IQVIA data, the addressable market for this injection was valued at approximately $50.7 million for the 12-month period ending January 2026. This launch is part of Glenmark's broader strategy to strengthen its injectable portfolio and expand its presence in the North American market.

Launching Potassium Phosphates Injection USP in 5 mL, 15 mL, and 50 mL vial sizes.
Distribution in the US market is scheduled to commence in March 2026.
Target market size is approximately $50.7 million based on IQVIA sales data ending January 2026.
Product is bioequivalent and therapeutically equivalent to Fresenius Kabi's reference listed drug (NDA 212832).

💡 Investors should monitor Glenmark's execution in the US injectable space, as this launch adds to their institutional channel revenue. While the market size is modest, it demonstrates consistent portfolio expansion in the high-margin US generics market.

Glenmark Gets USFDA Approval for Fluticasone Propionate with 180-Day Exclusivity

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 04 Mar 2026, 08:36 AM

Glenmark Specialty SA has received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol, a generic version of GSK's FloVent® HFA. The company has been granted 180-day Competitive Generic Therapy (CGT) exclusivity as the first approved applicant for this product. The target market for this therapy is valued at approximately $520.1 million annually as of January 2026. Commercial distribution in the U.S. is scheduled to begin immediately in March 2026, significantly strengthening Glenmark's respiratory portfolio.

Received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol (44 mcg)
Granted 180-day Competitive Generic Therapy (CGT) exclusivity as the first approved applicant
Targets a market with annual sales of approximately $520.1 million according to IQVIA data
Commercial launch in the U.S. market is scheduled for March 2026
Product is bioequivalent and therapeutically equivalent to FloVent® HFA by GlaxoSmithKline

💡 Investors should monitor the revenue contribution from this high-value launch during the 180-day exclusivity period, which is expected to improve U.S. margins. This approval validates Glenmark's technical capabilities in the complex respiratory segment.

Glenmark to Launch Sodium Phosphates Injection in US; Targets $66.8M Market

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 27 Feb 2026, 09:19 AM

Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Sodium Phosphates Injection USP in three single-dose vial presentations. The product is bioequivalent to Hospira's reference drug and is scheduled for distribution starting April 2026. According to IQVIA data, the market for this injection achieved annual sales of approximately $66.8 million for the 12-month period ending December 2025. This launch is part of Glenmark's strategy to expand its product portfolio within the US institutional channel.

Launch of Sodium Phosphates Injection USP in 15 mM, 45 mM, and 150 mM single-dose vials.
Distribution in the US market is set to begin in April 2026.
Targets a market segment with annual sales of approximately $66.8 million as of December 2025.
Product is bioequivalent and therapeutically equivalent to Hospira, Inc.’s reference listed drug.
Strengthens Glenmark's presence in the US institutional channel and injectable portfolio.

💡 Investors should monitor the successful rollout in April 2026 and the company's ability to capture market share from the $66.8 million pool. This launch supports Glenmark's long-term growth in the high-margin US injectables and institutional segments.

Glenmark Pharmaceuticals Assigned ESG Rating of 68 for FY 2025 by NSE Sustainability

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 20 Feb 2026, 05:29 PM

NSE Sustainability Ratings and Analytics Limited has independently assigned an ESG rating of 68 to Glenmark Pharmaceuticals for the 2025 financial year. The rating was based on publicly available information, as the company did not formally engage the agency for this assessment. This disclosure is made in compliance with SEBI's updated regulations regarding ESG rating disclosures. While the score provides a benchmark for sustainability, it does not impact the company's current financial operations or earnings outlook.

NSE Sustainability assigned an ESG rating of 68 for the financial year 2025.
The rating was determined independently using publicly available data without company engagement.
Disclosure follows SEBI Circular dated November 11, 2024, regarding ESG rating transparency.
The rating provides a standardized metric for institutional investors focused on ESG criteria.

💡 Investors should monitor this score as a benchmark for the company's sustainability performance relative to pharmaceutical peers. No immediate action is required as this is a non-financial regulatory update.

Glenmark Pharmaceuticals Releases Q3 FY26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 04 Feb 2026, 03:20 PM

Glenmark Pharmaceuticals has officially released the transcript of its earnings conference call held on February 2, 2026. The transcript covers the company's financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This document provides a detailed record of management's responses to analyst queries regarding business strategy and financial outlook. It is a standard regulatory filing following the announcement of quarterly results.

Transcript of the Earnings Call held on February 02, 2026, is now available for public review.
Covers financial performance and management commentary for Q3 and nine months ended December 31, 2025.
The filing is in compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015.
Provides transparency on analyst interactions and management's future guidance.

💡 Investors should review the transcript to gain deeper insights into management's perspective on R&D spend and market expansion plans. No immediate trading action is required based solely on this routine filing.

Glenmark Pharma Schedules Four Institutional Investor Conferences in Feb-Mar 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 04:39 PM

Glenmark Pharmaceuticals has announced its participation in four major institutional investor conferences scheduled between February 9 and March 9, 2026. The company will engage with investors at events hosted by Systematix, Axis Capital, Kotak Securities, and Investec in Mumbai. These sessions will include both group and one-on-one physical meetings to discuss business outlooks. The company explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during these interactions.

Participation in 4 major investor conferences between February 9 and March 9, 2026
Conferences hosted by Systematix, Axis Capital, Kotak Securities, and Investec
Meetings will be conducted in physical format in Mumbai
Engagement includes both group and one-on-one interaction types
Company confirmed no unpublished price sensitive information will be disclosed

💡 No immediate action is required as this is a routine disclosure. Investors should look for any investor presentations or transcripts released after these dates for updates on the company's strategic direction.

Glenmark Pharmaceuticals Releases Q3 FY 2025-26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 02 Feb 2026, 01:42 PM

Glenmark Pharmaceuticals has officially released the audio recording of its Q3 FY 2025-26 earnings conference call held on February 02, 2026. This disclosure is in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations. The recording provides a detailed account of management's discussion on the financial performance for the quarter ending December 31, 2025. Investors can access the link on the company's website to understand the strategic outlook and operational updates provided during the session.

Official audio recording of the Q3 FY 2025-26 earnings call is now available for public access.
The conference call was conducted on February 02, 2026, following the quarterly financial results announcement.
Filing made under Regulation 30 and 46 of SEBI LODR Regulations to ensure transparency.
The recording includes management commentary on business performance and responses to institutional investor queries.

💡 Investors should listen to the recording to understand management's perspective on margin trends and the R&D pipeline. It is a useful resource for assessing the company's future growth guidance and operational challenges.

GST Department Conducts 5-Day Search Operation at Glenmark Pharmaceuticals Offices

🔵 WATCH ⭐ 6/10

REGULATORY 📅 31 Jan 2026, 09:13 PM

The Goods & Service Tax (GST) Department, Mumbai, conducted a search and seizure operation at the offices of Glenmark Pharmaceuticals from January 27 to January 31, 2026. The inspection was carried out under Section 67 of the Maharashtra GST Act, 2017, and lasted for approximately five days. The company has stated that it fully cooperated with the officials and provided all requested documentation. Currently, no official document regarding adverse findings has been issued, and the company reports no material impact on its financials or operations.

Search operation conducted by Assistant Commissioner of State Tax (Investigation – B), Mumbai
Inspection commenced on January 27, 2026, and concluded on January 31, 2026
Action initiated under Section 67 of the Maharashtra Goods and Services Tax Act, 2017
Company reports no material impact on financial or operational activities at this stage
No official adverse findings or tax demand notices have been issued following the conclusion of the search

💡 Investors should monitor for any follow-up disclosures regarding tax demands or penalties resulting from this investigation. While the company claims no material impact, the five-day duration of the search warrants caution until a final clearance or demand notice is issued.

View All GLENMARK Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

India formulations grew 32% in FY25 (total revenue INR 13,321 Cr). The US market contracted by 2.5% in FY25. In Q2 FY26, India formulation sales were INR 165 Cr, an 87% decline from INR 1,281.7 Cr due to GST transition impacts. Consolidated revenue for H1 FY26 was INR 9,311.3 Cr, up 39.4% YoY.

Geographic Revenue Split

India (significant contributor with 32% growth in FY25), US (contraction of 2.5% in FY25), Europe and Rest of World (continued traction and growth).

Profitability Margins

Operating profitability improved from 10.1% in FY24 to 17.7% in FY25. Net profit was INR 687 Cr in FY25 compared to a loss of INR 1,686 Cr in FY24. The company targets an EBITDA margin of 23% in H2 FY26 and 25% in the future.

EBITDA Margin

EBITDA margin was 17.7% in FY25, up from 10.1% in FY24. The company aims for 23% in H2 FY26 and 25% long-term, driven by a shift to branded products and licensing income from the AbbVie deal.

Capital Expenditure

Planned annual capital expenditure is INR 700-800 Cr over the medium term to support growth and maintain 10 manufacturing facilities.

Credit Rating & Borrowing

CRISIL AA with a Stable outlook; short-term rating is CRISIL A1+. Ratings were reaffirmed following the USD 700 million AbbVie deal. The company repaid INR 1,300 Cr of gross debt post-deal.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents; however, 'benign input costs' were cited as a key driver for the margin improvement to 17.7% in FY25.

Capacity Expansion

The company currently operates 10 manufacturing facilities across India, the USA, and other countries. While specific MTPA expansion figures are not disclosed, the company plans to incur annual capital expenditure of INR 700-800 Cr over the medium term to support its 15% growth target.

Raw Material Costs

Raw material costs are described as 'benign' and 'stable', contributing to the improvement in operating margins to 17.7% in FY25. Specific cost as a % of revenue is not disclosed.

Manufacturing Efficiency

The company maintains an inventory level of 80 days, which is more efficient than the industry average of 90 days. This efficiency supports the H2 FY26 growth targets and was achieved through a one-time working capital correction of INR 1,600 Cr.

Logistics & Distribution

Distribution costs were impacted by freight and reverse logistics during the GST transition, contributing to the 87% decline in India primary sales in Q2 FY26. The company uses a unique 3-tier distribution system in India.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Glenmark 3.0 strategy targets 15% annual growth through a branded-led portfolio and innovation. The USD 700M AbbVie upfront payment will be used to reach zero debt, improving free cash flow for reinvestment. US growth is expected to revive with new launches, while India continues to outperform the market (10.8% vs 6.4% growth).

Products & Services

Pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs), and innovative assets like ISB 2001 (biologics).

Brand Portfolio

Glenmark, Ichnos Glenmark Innovation (IGI).

New Products/Services

ISB 2001 (partnered with AbbVie) and new US product launches are expected to drive future revenue. The AbbVie deal total value is USD 1.925 billion.

Market Expansion

Expansion is focused on Europe and Rest of World (ROW) markets, alongside a revival of the US market through new product launches.

Market Share & Ranking

Glenmark's India formulation business grew 10.8% in Q2 FY26, significantly outperforming the overall Indian pharma market growth of 6.4%.

Strategic Alliances

Exclusive global licensing deal with AbbVie Inc. for ISB 2001 (total value USD 1.925 billion) and the sale of a majority stake in Glenmark Life Sciences to Nirma Ltd in March 2024.

🌍 External Factors

Industry Trends

The industry is shifting toward innovation-led biotech deals (e.g., USD 1.925B AbbVie deal) and branded portfolios (Glenmark 3.0) to achieve 25% margins and offset generic pricing pressure in the US (2.5% contraction).

Competitive Landscape

Key competitors include other large Indian pharma companies. Glenmark competes by outperforming market growth (10.8% vs 6.4%) and moving into innovative biologics to differentiate from generic peers.

Competitive Moat

The company's moat is built on its robust R&D platform, specifically through Ichnos Glenmark Innovation (IGI), which successfully developed ISB 2001. This asset's validation through a USD 1.925 billion deal with AbbVie creates a competitive advantage in the innovative biologics space.

Macro Economic Sensitivity

The business is sensitive to regulatory changes like the GST regime, which caused an 87% temporary drop in India sales. It is also exposed to US market dynamics, where a lack of new launches led to a 2.5% revenue contraction.

Consumer Behavior

Demand is driven by a strong position in the chronic therapeutic segment in India, which is fast-growing and less sensitive to short-term economic shifts than acute segments.

Geopolitical Risks

The company operates 10 facilities globally and exports to developing nations, exposing it to trade barriers and regulatory risks in diverse international markets.

⚖️ Regulatory & Governance

Industry Regulations

Operations are affected by pricing controls (e.g., INR 900.1 Cr settlement for pricing practices), manufacturing standards across 10 global facilities, and tax regime changes like GST which impacted India sales by 87%.

Environmental Compliance

The company has a board-level ESG committee to monitor its ESG strategy and action plans. Specific compliance costs in INR are not disclosed.

Taxation Policy Impact

The company paid INR 75 Cr in cash tax as part of its Q2 FY26 cash flow reconciliation. It aims for tax efficiencies through balance sheet restructuring.

Legal Contingencies

Exceptional losses of INR 372.8 Cr in FY25 and INR 900.1 Cr in FY24 for legal settlements regarding pricing and other claims. These settlements significantly impact cash generation and debt metrics.

⚠️ Risk Analysis

Key Uncertainties

Key risks include the uncertain returns on high R&D investments (7% of sales), potential for sluggish business performance impacting the 15% growth target, and further stretch in the working capital cycle.

Geographic Concentration Risk

India formulations (32% growth in FY25) and the US market (-2.5% contraction) are the primary regions. The US market's performance is a key risk factor for overall top-line improvement.

Technology Obsolescence Risk

The company is mitigating technology risks by transitioning to 'Glenmark 3.0', focusing on innovative biologics (ISB 2001) to move up the value chain and avoid the obsolescence of traditional generic manufacturing.

Credit & Counterparty Risk

Receivables quality is being addressed by discontinuing legacy pre-collection practices and taking a one-time INR 1,600 Cr provision for debtors and inventory to ensure the balance sheet reflects true capital efficiency.